Aflibercept
Contents
Description
Aflibercept is a recombinant fusion protein that acts as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). It is administered as an intravitreal injection for the treatment of various retinal diseases including age-related macular degeneration. The drug provides sustained VEGF inhibition to reduce retinal fluid and improve vision.
Indications & Therapeutic Use
neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Aflibercept — GNH India
47 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | aflibercept |
| Brands | 1 brand available |
| Active Ingredient | aflibercept |
| Drug Class | neovascular age-related macular degeneration |
| Manufacturer | Regeneron Pharmaceuticals |
| Dosage Forms | intravitreal injection, 40 mg/mL solution |
| Medical Code | S01LA05 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00509795 |
| Countries | 10 countries |